Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1…
Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango…
Read More...
Read More...
